- Home
- LUCD vs QTRX Comparison
LUCD vs QTRX Comparison
Compare LUCD & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | QTRX |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | 82 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2M | 160.0M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LUCD | QTRX |
|---|---|---|
| Price | $1.02 | $2.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | $4.13 | ★ $6.00 |
| AVG Volume (30 Days) | 901.2K | ★ 1.4M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,346,000.00 | ★ $37,632,000.00 |
| Revenue This Year | $115.58 | $25.49 |
| Revenue Next Year | $130.54 | $10.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.00 | 64.52 |
| 52 Week Low | $0.90 | $2.40 |
| 52 Week High | $1.70 | $8.77 |
Technical Indicators
Market Signals| Indicator | LUCD | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 36.62 |
| Support Level | N/A | N/A |
| Resistance Level | $1.12 | $3.74 |
| Average True Range (ATR) | 0.06 | 0.29 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 50.00 | 23.01 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.